35 results about "Hypofunctions" patented technology

The invention relates to the technical field of biomarkers, in particular to a blood biomarker combination for prediction and auxiliary diagnosis of ovarian reserve hypofunction (DOR), a corresponding detection kit and application of the blood biomarker combination. According to the invention, the content change of the nicotinamide mononucleotide (NMN) and the metabolite combination thereof in serum or plasma is screened for the first time and can be used as a detection index for predicting the ovarian reserve function decline. Based on the biomarker combination, the invention further provides an in-vitro detection kit containing a related standard substance, an internal standard solution and an extracting solution, and a data analysis method combined with a random forest model, so that an individual with a normal ovarian reserve function and an individual with hypofunction can be accurately distinguished. The method is noninvasive, simple, convenient, high in sensitivity and suitable for early recognition and layered screening of clinical ovarian reserve hypofunction.

A stable sustained release injectable formulation based on poly(D,L-lactide-co-glycolide) microparticles comprising levothyroxine is described. The formulation has a theoretical levothyroxine loading of at least 1.5% w / w. A process for preparing the microparticles is also described. The formulation may be used to control hypothyroidism in adults, congenital hypothyroidism in infants, and acquired hypothyroidism in children.

The invention discloses a traditional Chinese medicine composition, a traditional Chinese medicine extract, a pharmaceutical preparation and application for treating hypoovarian reserve function. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 12 to 18 parts of radix astragali seu hedysari, 9 to 15 parts of radix angelicae sinensis, 9 to 15 parts of fructus ligustri lucidi, 9 to 15 parts of fructus mori, 9 to 15 parts of semen cuscutae, 6 to 12 parts of cornu cervi degelatinatum, 7 to 13 parts of tortoise shell and 7 to 13 parts of radix cyathulae. The traditional Chinese medicine composition, the traditional Chinese medicine extract and the pharmaceutical preparation are low in cost and high in safety, and can remarkably improve the ovarian function of an elderly patient suffering from hypoovarian reserve function, increase the number of sinus follicles and improve the follicle quality.

The invention provides a traditional Chinese medicine composition for treating hypothyroidism and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. In the traditional Chinese medicine composition, fomes officinalis ames, stigma croci, aloe, resina scammoniae, kalimeris indica, radix aucklandiae, pogonatherum crinitum and rhizoma nardostachyos are taken as main medicines of a formula, asamur, cortex cinnamomi, rhizoma calami, myrrh branches, euphorbia pekinensis resina, common jasminum seeds and champignon are taken as auxiliary medicines of the formula, and vernonia anthelmintica, hypericum perforatum, black pepper and white pepper are taken as correction medicines of the formula. The traditional Chinese medicine composition is clear in compatibility, has the effects of promoting blood circulation to remove blood stasis, eliminating cold to stop pain, relaxing tendons and activating collaterals and tonifying the liver and kidney, can effectively treat hypothyroidism, and is definite in curative effect on improvement of clinical manifestations and laboratory indexes of patients, safe and reasonable.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods for the prevention or treatment of osteoporosis, bone fractures, osteomalacia, arthritis, thrombocytopenia, parathyroid hypofunction, hyperphosphatemia, or neoplastic calcaremia.

The invention provides a method of treating or controlling hypoparathyroidism in a human patient by administering to the human patient a pharmaceutical composition comprising a controlled-release PTH compound or a pharmaceutically acceptable salt thereof. The controlled-release PTH compound comprises a PTH moiety reversibly conjugated to a branched polyethylene glycol carrier. The composition is administered by subcutaneous injection no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered by subcutaneous injection at the same dosing frequency required to maintain a serum albumin-adjusted calcium level in serum of above 8.5 mg / dL over a 24 hour period.

A method for treating a patient suffering from a neuronal hypo-kinetic disease or a neuronal hyper-kinetic disease by modulating neuronal activity in the: internal globus pallidus (GPi), in the anterior motor thalamus and / or in the external globus pallidum (GPe) and / or in the subthalamic nucleus (STN) by utilizing suppressor and / or enhancer DREADDs is provided.

The present invention relates to methods of treating hypogonadism in a male subject through administering intranasally to the male subject an intranasal testosterone bio-adhesive gel formulation to deliver a therapeutically effective amount of testosterone. In particular, the testosterone therapy of the invention remains effective if an allergic rhinitis event occurs in the male during the treatment or when the male subject uses a topical nasal vasoconstrictor or a topical intranasal decongestant during the hypogonadism treatment. Further, the present invention relates to a method of preventing Hie occurrence of an allergic rhinitis event in a male, who is undergoing a hypogonadism treatment with an intranasal testosterone bio-adhesive gel. In certain embodiments, the intranasal testosterone bio-adhesive gel formulation according to the invention comprises 4.0% and 4.5% testosterone.

The present invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising the same. The present invention further relates to PTH compositions having improved serum half-life and peak-to-trough ratio and methods for controlling serum calcium levels using the PTH variants and compositions of the present invention. The present invention further relates to methods for treating hypoparathyroidism and / or hypocalcemia caused by hypoparathyroidism using the PTH variants and compositions of the present invention.

Disclosed are a compound that is a parathyroid hormone receptor 1 agonist and a method useful for preventing or treating osteoporosis, fractures, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia, or neoplastic calcification.

The invention discloses application of glossy privet fruit glycoside in preparation of a medicine for treating senile cardiac hypofunction, belongs to the technical field of medicines, and particularly relates to the application of the glossy privet fruit glycoside in preparation of the medicine for treating senile cardiac hypofunction. The polypeptide can effectively improve myocardial hypertrophy and cardiac function impairment of old mice, reduce myocardial fibrosis, reduce inflammation and senescence marker levels, and have potential application value in anti-aging and heart protection aspects.

The present technology generally relates to a method for management and / or treatment of hypoparathyroidism (HP) in a subject. The method comprises administering a dose of a PTH compound to the subject, wherein the PTH compound has an amino acid sequence as set forth in SEQ ID NO: 10; and wherein administration of the PTH compound maintains or improves bone integrity.

The invention belongs to the technical field of microorganisms, and particularly discloses application of lactobacillus rhamnosus fermented milk in a product for improving male functions. According to the application, the new application of the lactobacillus rhamnosus B6 (CGMCC No.13310) fermented milk in the aspect of improving male functions is disclosed for the first time, and the new application is specifically characterized by improving male fertility desire, reproductive capacity, seminiferous tubule dysfunction and spermatogenesis, testis oxidative stress activity, testis testosterone synthesis and sperm quality; the strain has a potential value of producing a gain substance for improving the male function by fermenting skimmed milk, and also prompts that the fermented milk has a potential application prospect for enhancing the male function.

Compositions and methods for treating parathyroid hypofunction in a subject are provided. A viral vector is provided comprising a nucleic acid molecule comprising a sequence encoding a PTH fusion protein and a regulatory sequence that directs the expression thereof.

The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and / or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.

The invention relates to the technical field of biological medicine. The invention provides an application of a small molecule compound P077-0472 in preparation of a medicine for preventing and / or treating myocardial injury caused by hypothyroidism. The structural formula of the small molecule compound P077-0472 is as shown in formula (I). According to the technical scheme, the small molecule compound P077-0472 capable of promoting the dephosphorylation function of DUSP14 is screened out, and the inhibition of the small molecule compound on necroptosis and the improvement effect on subsequent cell damage are verified in a model of necroptosis caused by hypothyroidism.

The invention provides a traditional Chinese medicine composition for treating thyroid postoperative parathyroid hypofunction (hereinafter referred to as subthyroid hyperthyroidism). Specifically, the invention develops a traditional Chinese medicine composition for treating thyroid postoperation combined parathyroid hypofunction for the first time, and the traditional Chinese medicine composition is prepared from the following raw material medicines: 240g of raw astragalus membranaceus, 12g of angelica sinensis, 9g of radix paeoniae rubra, 6g of ligusticum wallichii, 6g of lumbricus, 6g of fried peach kernel, 6g of safflower and 12g of kudzu vine root. The traditional Chinese medicine composition can improve the PTH recovery rate, shorten the PTH recovery time, reduce the total calcium supplement amount, relieve low-calcium clinical symptoms caused by thyroid subtraction after the thyroid surgery to a certain extent, promote qi and blood circulation of the whole body after the surgery, prevent thrombosis, promote wound healing and shorten the hospitalization time at the same time, meets the clinical requirements, and is worthy of popularization and application. The current situation that traditional Chinese medicine prescriptions combined with parathyroid hypofunction after thyroid surgery are insufficient is made up.

Compositions and methods for treating hypoparathyroidism in a subject are provided. A viral vector is provided that includes a nucleic acid molecule that includes a sequence encoding a PTH fusion protein and a regulatory sequence that directs its expression.

The application discloses a processed American ginseng product for treating hypothyroidism, which is prepared from American ginseng as raw material and is obtained through nine times of steaming and drying; the black American ginseng is crushed into coarse powder, and is extracted three times through heating reflux extraction with 50-70% ethanol solution, and each time is 1-3 hours, and the extract is concentrated to obtain the product. The application further discloses application of the processed American ginseng product in preparation of a medicine for treating hypothyroidism. The processed American ginseng product can improve the unbalanced hypothalamus-pituitary-thyroid axis function of a hypothyroidism patient, promote secretion of thyroid hormone, improve thyroid function, and has a remarkable improvement effect on hypothyroidism.

Methods and compositions are disclosed for diagnosing a patient suspected of suffering from, and for treating a patient suffering from, a disorder such as hypercortisolemia, metabolic syndrome, pre-diabetes, diabetes, Cushing's syndrome, Cushing's Disease, hyperglycemia secondary to hypercortisolemia, a liver disease, a cardiac disorder, high blood pressure, a blood clotting disorder, a cancer, a psychological disorder, weight gain, a disorder of glucose control, a bone disorder (e.g., osteoporosis), hypogonadism, pseudoacromegaly, pituitary tumors, functional hypercortisolism, ACTH secreting tumors, peripheral neuropathy, dyslipidemia and other disorders.The methods and compositions include administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (GRM). The preferred heteroaryl-ketone fused azadecalin GRM is relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone). In some cases, the GRM (e.g., relacorilant) is orally administered. In some cases, the GRM (e.g., relacorilant) is orally administered without food.

The present invention relates to a PTH compound for use in the treatment of chronic hypoparathyroidism, wherein the treatment comprises the step of administering to a patient having chronic hypoparathyroidism a once weekly dose of a PTH compound and wherein prior to initiation of the treatment the patient is clinically determined as being no longer dependent on active vitamin D and calcium supplement to maintain serum within normal range; and related aspects.

The application discloses an exosome preparation for treating hypofunction of ovary and a preparation method and application thereof, and belongs to the technical field of biological medicine, and particularly relates to a preparation method of an exosome preparation for treating hypofunction of ovary, which comprises the following steps: taking perinatal stem cells, subculturing, obtaining domesticated perinatal stem cells, digesting, expanding and culturing to a density of 80%-85%, adding a culture medium for culturing, collecting supernatant, collecting supernatant for 3 times, combining, filtering through a 0.45 mu m PES filter membrane first, and then concentrating to obtain a concentrated solution; centrifuging, resuspending a precipitate, purifying through a density gradient, obtaining an exosome precipitate, and suspending the exosome precipitate in a cryopreservation protective solution to obtain the exosome preparation. The application provides the exosome preparation for treating hypofunction of ovary and the preparation method and application thereof, a safe, sufficient, high-purity and stable exosome preparation is prepared, and the stem cell exosome for treating hypofunction of ovary is provided.

The invention discloses a novel exosome composition as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The composition is obtained by mixing exosome, nicotinamide adenine dinucleotide or a precursor thereof and ginsenoside, can play a synergistic effect of different action mechanisms, and can significantly enhance the cognitive function to treat diseases related to brain hypofunction compared with single use of one component. Moreover, the components are all natural products existing in the nature, and clinical intravenous injection products have better safety in actual use. The composition can be applied to preparation of products for treating brain memory hypofunction, and is used for treating brain hypofunction caused by memory hypofunction, Alzheimer's disease, ischemic cerebral apoplexy sequelae and the like. The invention provides a detailed product preparation method and use guidance, and the effectiveness and safety of the traditional Chinese medicine composition are verified through a product pharmacodynamic embodiment.

This invention provides a mouse model of hypothyroidism combined with pulmonary hypertension, its construction method, and its application, belonging to the field of animal experimental model construction technology. In this invention, a hypothyroid mouse model was obtained by intragastric administration of methimazole and feeding mice under normoxic conditions. The hypothyroid mouse model was then further modified by intragastric administration of methimazole, followed by continuous subcutaneous injection of the vascular endothelial growth factor inhibitor Su5416, and feeding the mice under hypoxic conditions to obtain a mouse model of hypothyroidism combined with pulmonary hypertension. This invention successfully established a stable mouse model of hypothyroidism combined with pulmonary hypertension through a combination of drug intervention and hypoxic feeding.

The invention provides an application of a methoxy isoflavone compound in prevention and treatment of premature ovarian failure. A large number of studies find that the biochanin A and formononetin can effectively improve ovarian reserve function decline or estrus cycle disorder caused by premature senility, adjust the estrogen level, promote follicle development and maturity, increase the ovarian index, increase ovarian reserve and recover the ovarian function. Meanwhile, the biochanin A and the formononetin have the advantages of good stability, high biological activity and low toxicity, can be safely used for preparing medicines for preventing or / and treating ovarian reserve hypofunction and premature senility, and have good patent medicine prospects.

A detector system for non-invasively detecting exacerbation of heart hypofunction comprises a sensor (102) configured to produce a measurement signal when being in a movement sensing relation with a jugular vein (105) of an individual. The detector system comprises a processing system (101) configured to receive the measurement signal, and a memory system (103) communicatively connected to the processing system. As changes in high frequency oscillations in jugular vein pressure can be indicative of development of heart hypofunction, the processing system is configured to compare first data stored in the memory system and based on an earlier produced measurement signal to second data based on a later produced measurement signal, and to form indicator data indicative of exacerbation of heart hypofunction based on the comparison between the first data and the second data.

Compositions and methods for treating hypoparathyroidism in a subject are provided. A viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding a PTH fusion protein and regulatory sequences which direct expression thereof.

The invention discloses a phthalazinone compound as shown in a formula I, or an enantiomer, a diastereoisomer, a raceme, a cis-trans-isomer, a deuterated compound, a metabolite, a solvate, a hydrate, a pharmaceutically acceptable salt or eutectic thereof, and a preparation method, a pharmaceutical composition and application thereof. The compound disclosed by the invention is good in liver targeting property and low in side effect; the compound has a good application prospect in preparation of drugs for thyroid hormone receptor related diseases (obesity, dyslipidemia, hypercholesteremia, diabetes and other related diseases and diseases), and non-alcoholic fatty liver (NASH), non-alcoholic fatty liver disease (NAFLD), atherosclerosis, cardiovascular diseases, hypothyroidism and other related diseases and diseases). # imgabs0 #